Predicting the impact of a partially effective HIV vaccine and subsequent risk behavior change on the heterosexual HIV epidemic in low- and middle-income countries: A South African example

Journal of Acquired Immune Deficiency Syndromes

Volumn 46, Issue 1, 2007, Pages 78-90

  Andersson, Kyeen M ^a   Owens, Douglas K ^b,c   Vardas, Eftyhia ^d   Gray, Glenda E ^d   McIntyre, James A ^d   Paltiel, A David ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c STANFORD UNIVERSITY   (United States)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Africa; AIDS vaccines; Condoms; Heterosexual transmission; Mathematical models; Models projections; Sexual behavior

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ARTICLE; BEHAVIOR CHANGE; CONDOM; DEATH; DRUG EFFICACY; FEMALE; GENDER; HETEROSEXUALITY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCOME; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; PREVALENCE; PRIORITY JOURNAL; RISK; SOUTH AFRICA; VACCINATION;

AIDS VACCINES; COMPUTER SIMULATION; CONDOMS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MODELS, BIOLOGICAL; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEX FACTORS; SOCIOECONOMIC FACTORS; SOUTH AFRICA; TIME FACTORS; UNSAFE SEX;

EID: 34848910202     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31812506fd     Document Type: Article

References (78)

1. VaxGen, Inc. Press release. February 24, 2003. Available at: http://www.vaxgen.com. Accessed January 15, 2007.
2. International AIDS Vaccine Initiative. IAVI database of AIDS vaccines in human trial [database online]. New York, NY: International AIDS Vaccine Initiative; 2006. Updated June 13, 2006. Available at: http://www.iavi.org. Accessed January 15, 2007.
3. Garber DA, Silvestri G, Feinberg MB. Prospects for an AIDS vaccine: three big questions, no easy answers. Lancet Infect Dis. 2004;4:397-413.
4. Self S. Vaccine efficacy trial design: role of Phase IIb vs. Phase III trials [56]. Presented at: AIDS Vaccine International Conference; 2005; Montreal.
5. Anonymous. Future access to HIV vaccines. Report from a WHOUNAIDS Consultation, Geneva, 2-3 October 2000. AIDS. 2001;15:W27-W44.
6. Bishai D, Pariyo G, Ainsworth M, et al. Determinants of personal demand for an AIDS vaccine in Uganda: contingent valuation survey. Bull World Health Organ. 2004;82:652-660.
7. Newman PA, Duan N, Rudy ET, et al. Challenges for HIV vaccine dissemination and clinical trial recruitment: if we build it, will they come? AIDS Patient Care STDS. 2004;18:691-701.
8. Newman PA, Duan N, Rudy ET, et al. Posttrial HIV vaccine adoption: concerns, motivators, and intentions among persons at risk for HIV. J Acquir Immune Defic Syndr. 2004;37:1393-1403.
9. Lurie P, Bishaw M, Chesney MA, et al. Ethical, behavioral, and social aspects of HIV vaccine trials in developing countries. JAMA. 1994;271:295-301.
10. Cohen J. The HIV vaccine paradox. Science. 1994;264:1072-1074.
11. Halloran ME, Longini IM Jr, Haber MJ, et al. Exposure efficacy and change in contact rates in evaluating prophylactic HIV vaccines in the field. Stat Med. 1994;13:357-377.
12. Schaper C, Fleming TR, Self SG, et al. Statistical issues in the design of HIV vaccine trials. Annu Rev Public Health. 1995;16:1-22.
13. Frey SE. Unique risks to volunteers in HIV vaccine trials. J Investig Med. 2003;51(Suppl 1):S18-S20.
14. Blower S, Schwartz EJ, Mills J. Forecasting the future of HIV epidemics: the impact of antiretroviral therapies and imperfect vaccines. AIDS Rev. 2003;5:113-125.
15. Anderson RM, Garnett GP. Low-efficacy HIV vaccines: potential for community-based intervention programmes. Lancet. 1996;348:1010-1013.
16. Anderson RM, Swinton J, Garnett GP. Potential impact of low efficacy HIV-1 vaccines in populations with high rates of infection. Proc Biol Sci. 1995;261:147-151.
17. Stover J, Garnett GP, Seitz S, et al. The epidemiological impact of an HIV/AIDS vaccine in developing countries [World Bank Policy Research Working Paper No. 2811]. The World Bank Development Research Group, March 2002. Available at: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=636094. Accessed January 15, 2007.
18. Gray RH, Li X, Wawer MJ, et al. Stochastic simulation of the impact of antiretroviral therapy and HIV vaccines on HIV transmission; Rakai, Uganda. AIDS. 2003;17:1941-1951.
19. Owens DK, Edwards DM, Shachter RD. Population effects of preventive and therapeutic HIV vaccines in early- and late-stage epidemics. AIDS. 1998;12:1057-1066.
20. Anderson R, Hanson M. Potential public health impact of imperfect HIV type 1 vaccines. J Infect Dis. 2005;191(Suppl 1):S85-S96.
21. Blower SM, Koelle K, Kirschner DE, et al. Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety. Proc Natl Acad Sci USA. 2001;98:3618-3623.
22. Amirfar S, Hollenberg JP, Abdool Karim SS. Modeling the impact of a partially effective HIV vaccine on HIV infection and death among women and infants in South Africa. J Acquir Immune Defic Syndr. 2006;43:219-225.
23. Blower SM, McLean AR. Prophylactic vaccines, risk behavior change, and the probability of eradicating HIV in San Francisco. Science. 1994;265:1451-1454.
24. Bogard E, Kuntz KM. The impact of a partially effective HIV vaccine on a population of intravenous drug users in Bangkok, Thailand: a dynamic model. J Acquir Immune Defic Syndr. 2002;29:132-141.
25. Edwards DM, Shachter RD, Owens DK. A dynamic HIV-transmission model for evaluating the costs and benefits of vaccine programs. Interfaces. 1998;28:144-166.
26. Smith RJ, Blower SM. Could disease-modifying HIV vaccines cause population-level perversity? Lancet Infect Dis. 2004;4:636-639.
27. Davenport MP, Ribeiro RM, Chao DL, et al. Predicting the impact of a nonsterilizing vaccine against human immunodeficiency virus. J Virol. 2004;78:11340-11351.
28. Francis DP, Heyward WL, Popovic V, et al. Candidate HIV/AIDS vaccines: lessons learned from the world's first phase III efficacy trials. AIDS. 2003;17:147-156.
29. Bartholow BN, Buchbinder S, Celum C, et al. HIV sexual risk behavior over 36 months of follow-up in the world's first HIV vaccine efficacy trial. J Acquir Immune Defic Syndr. 2005;39:90-101.
30. van Griensvan F, Keawkungwal J, Tappero JW, et al. Lack of increased HIV risk behavior among injection drug users participating in the AIDSVAX B/E HIV vaccine trial in Bangkok, Thailand. AIDS. 2004;18:295-301.
31. Rerks-Ngam S, Pitisuttithum P, Nitayaphan S, et al. An update of progress in the Thai HIV prime boost vaccine trial: VCP1521 (ALVAC-HIV) + GP120 B/E (AIDSVAX B/E) [31]. Presented at: AIDS Vaccine International Conference; 2005; Montreal.
32. Lampinen TM, Chan K, Remis RS, et al. Sexual risk behaviour of Canadian participants in the first efficacy trial of a preventive HIV-1 vaccine. Can Med Assoc J. 2005;172:479-483.
33. Chesney MA, Chambers DB, Kahn JO. Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:266-271.
34. HIV Vaccine Trials Network. HIV Vaccine Trials Network current vaccine trials [database online]. Seattle, WA: HIV Vaccine Trials Network; 2006. Updated September 2006. Available at: http://www.hvtn.org. Accessed January 15, 2007.
35. Sandstrom E, Birx D. HIV vaccine trials in Africa. AIDS. 2002;16(Suppl 4):S89-S95.
36. Jackson DJ, Martin HL Jr, Bwayo JJ, et al. Acceptability of HIV vaccine trials in high-risk heterosexual cohorts in Mombasa, Kenya. AIDS. 1995;9:1279-1283.
37. Mesesan K. Implementing partially effective HIV prevention programs: changes in sexual risk behavior and epidemic impact in sub-Saharan Africa [doctoral thesis]. New Haven, CT: Department of Epidemiology and Public Health, Yale University School of Medicine; 2007.
38. Dorrington R, Bradshaw D, Budlender D. HIV/AIDS Profile in the Provinces of South Africa: Indicators for 2002. Cape Town, South Africa: University of Cape Town Centre for Actuarial Research, South African Medical Research Council Burden of Disease Research Unit, and Actuarial Society of South Africa; 2002.
39. Dorrington R, Bradshaw D, Johnson L, et al. The Demographic Impact of HIV/AIDS in South Africa: National Indicators for 2004. Cape Town, South Africa: University of Cape Town Centre for Actuarial Research, South African Medical Research Council Burden of Disease Research Unit, and Actuarial Society of South Africa; 2004.
40. Joint United Nations Program on HIV/AIDS. 2006 Report on the global AIDS epidemic, May 2006. Available at: http://www.unaids.org/en/HIV_data/ 2006GlobalReport/default.asp. Accessed January 15, 2007.
41. Statistics South Africa. 2001 South African census. 2004. Available at: http://www.statssa.gov.za. Accessed January 15, 2007.
42. Anonymous. Mid-Year Population Estimates, South Africa: 2004. Pretoria, South Africa: Statistics South Africa; 2004.
43. Actuarial Society of South Africa. ASSA2000 model. 2004. Available at: http://www.assa.org.za/. Accessed January 15, 2007.
44. Simbayi LC, Chauveau J, Shisana O. Behavioural responses of South African youth to the HIV/AIDS epidemic: a nationwide survey. AIDS Care. 2004;16:605-618.
45. Pettifor AE, Rees HV, Steffenson A, et al. HIV and Sexual Behavior Among Young South Africans: A National Survey of 15-24 Year Olds. Johannesburg, South Africa: Reproductive Health Research Unit, University of the Witwatersrand; 2004.
46. Pettifor AE, Rees HV, Kleinschmidt I, et al. Young people's sexual health in South Africa: HIV prevalence and sexual behaviors from a nationally representative household survey. AIDS. 2005;19:1525-1534.
47. Shisana O, Rehle T, Simbayi LC, et al. South African National HIV Prevalence, HIV Incidence, Behaviour and Communication Survey, 2005. Cape Town, South Africa: HSRC Press; 2005.
48. Anderson RM, Gupta S, May RM. Potential of community-wide chemotherapy or immunotherapy to control the spread of HIV-1. Nature. 1991;350:356-359.
49. McLean AR, Blower SM. Imperfect vaccines and herd immunity to HIV. Proc Biol Sci. 1993;253:9-13.
50. Mesesan K, Van Niekirk RM, Niccolai LM, et al. Self-reported sexual risk behaviors of a cohort being prepared for multiple Phase I/II HIV vaccine trials in Soweto, South Africa [OA06-05]. Presented at: AIDS Vaccine International Conference; 2006; Amsterdam.
51. Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet. 2001;357:1149-1153.
52. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis. 2005;191:1403-1409.
53. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med. 2000;342:921-929.
54. Baeten JM, Richardson BA, Lavreys L, et al. Female-to-male infectivity of HIV-1 among circumcised and uncircumcised Kenyan men. J Infect Dis. 2005;191:546-553.
55. Gray RH, Li X, Kigozi G, et al. Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study. Lancet. 2005;366:1182-1188.
56. Fideli US, Allen SA, Musonda R, et al. Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses. 2001;17:901-910.
57. Bunnell R, Ekwaru JP, Solberg P, et al. Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS. 2006;20:85-92.
58. Morgan D, Mahe C, Mayanja B, et al. HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? AIDS. 2002;16:597-603.
59. Anonymous. Workshop Summary: Scientific Evidence of Condom Effectiveness for Sexually Transmitted Disease (STD) Prevention. Herndon, VA: National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services; 2000.
60. Simbayi L, Strebel A, Wilson T, et al. Sexually Transmitted Diseases in the South African Public Sector. National Department of Health's Directorate of Health Systems Research and Epidemiology in conjunction with the Directorate of HIV/AIDS and STDs; Belville, South Africa. 1999.
61. Williams BG, Taljaard D, Campbell CM, et al. Changing patterns of knowledge, reported behaviour and sexually transmitted infections in a South African gold mining community. AIDS. 2003;17:2099-2107.
62. Pettifor AE, Measham DM, Rees HV, et al. Sexual power and HIV risk, South Africa. Emerg Infect Dis. 2004;10:1996-2004.
63. Ackermann L, de Klerk GW. Social factors that make South African women vulnerable to HIV infection. Health Care Women Int. 2002;23:163-172.
64. Blower SM, Bodine EN, Grovit-Ferbas K. Predicting the potential public health impact of disease-modifying HIV vaccines in South Africa: the problem of subtypes. Curr Drug Targets Infect Disord. 2005;5:179-192.
65. World Health Organization/Joint United Nations Program on HIV/AIDS. Progress on global access to HIV antiretroviral therapy: a report on "3 by 5" and beyond. March 2006. Available at: http://www.who.int/hiv/ fullreport_en_highres.pdf. Accessed January 15, 2007.
66. Department of Health, South Africa. Monitoring Review: Progress Report on the Implementation of the Comprehensive HIV and AIDS Care, Management and Treatment Programme. Pretoria, South Africa: Department of Health; 2004.
67. International AIDS Vaccine Initiative. AIDS vaccine blueprint, 2006. Available at: http://www.iavi.org/blueprint. Accessed January 15, 2007.
68. Wasserheit JN. Clinical trials: state of the field in the era of efficacy trials of CTL-mediated HIV vaccines [55]. Presented at: AIDS Vaccine International Conference; 2005; Montreal.
69. Levy JA. What can be achieved with an HIV vaccine? Lancet. 2001;357:223-224.
70. Walensky RP, Paltiel AD, Goldie SJ, et al. A therapeutic HIV vaccine: how good is good enough? Vaccine. 2004;22:4044-4053.
71. Kaul R, Kimani J, Nagelkerke NJ, et al. Reduced HIV risk-taking and low HIV incidence after enrollment and risk-reduction counseling in a sexually transmitted disease prevention trial in Nairobi, Kenya. J Acquir Immune Defic Syndr. 2002;30:69-72.
72. Brandeau ML, Owens DK, Sox CH, et al. Screening women of childbearing age for human immunodeficiency virus. A cost-benefit analysis. Arch Intern Med. 1992;152:2229-2237.
73. Pequegnat W, Fishbein M, Celentano D, et al. NIMH/APPC workgroup on behavioral and biological outcomes in HIV/STD prevention studies: a position statement. Sex Transm Dis. 2000;27:127-132.
74. Kaplan EH. Modeling HIV infectivity: must sex acts be counted? J Acquir Immune Defic Syndr. 1990;3:55-61.
75. Auvert B, Taljaard D, Lagarde E, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005;2:e298.
76. Mesesan K, Owens DK, Paltiel AD. The potential benefits of expanded male circumcision programs in Africa: predicting the population-level impact on heterosexual HIV transmission in Soweto [TUAC0203]. Presented at: XVI International AIDS Conference; 2006; Toronto.
77. Centre for AIDS Development, Research and Evaluation. HIV prevalence, incidence, behavior and communication survey, 2005. 2006. Available at: http://www.cadre.org.za. Accessed January 15, 2007.
78. Actuarial Society of South Africa. ASSA2003 model. 2005. Available at: http://www.assa.org.za/. Accessed January 15, 2007.